Unknown

Dataset Information

0

High-fidelity Glucagon-CreER mouse line generated by CRISPR-Cas9 assisted gene targeting.


ABSTRACT:

Objective

α-cells are the second most prominent cell type in pancreatic islets and are responsible for producing glucagon to increase plasma glucose levels in times of fasting. α-cell dysfunction and inappropriate glucagon secretion occur in both type 1 and type 2 diabetes. Thus, there is growing interest in studying both normal function and pathophysiology of α-cells. However, tools to target gene ablation or activation specifically of α-cells have been limited, compared to those available for β-cells. Previous Glucagon-Cre and Glucagon-CreER transgenic mouse lines have suffered from transgene silencing, and the only available Glucagon-CreER "knock-in" mouse line results in glucagon haploinsufficiency, which can confound the interpretation of gene deletion analyses. Therefore, we sought to develop a Glucagon-CreERT2 mouse line that would maintain normal glucagon expression and would be less susceptible to transgene silencing.

Methods

We utilized CRISPR-Cas9 technology to insert an IRES-CreERT2 sequence into the 3' UTR of the Glucagon (Gcg) locus in mouse embryonic stem cells (ESCs). Targeted ESC clones were then injected into mouse blastocysts to obtain Gcg-CreERT2 mice. Recombination efficiency in GCG+ pancreatic α-cells and glucagon-like peptide 1 positive (GLP1+) enteroendocrine L-cells was measured in Gcg-CreERT2 ;Rosa26-LSL-YFP mice injected with tamoxifen during fetal development and adulthood.

Results

Tamoxifen injection of Gcg-CreERT2 ;Rosa26-LSL-YFP mice induced high recombination efficiency of the Rosa26-LSL-YFP locus in perinatal and adult α-cells (88% and 95%, respectively), as well as in first-wave fetal α-cells (36%) and adult enteroendocrine L-cells (33%). Mice homozygous for the Gcg-CreERT2 allele were phenotypically normal.

Conclusions

We successfully derived a Gcg-CreERT2 mouse line that expresses CreERT2 in pancreatic α-cells and enteroendocrine L-cells without disrupting preproglucagon gene expression. These mice will be a useful tool for performing temporally controlled genetic manipulation specifically in these cell types.

SUBMITTER: Ackermann AM 

PROVIDER: S-EPMC5323890 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

High-fidelity <i>Glucagon-CreER</i> mouse line generated by CRISPR-Cas9 assisted gene targeting.

Ackermann Amanda M AM   Zhang Jia J   Heller Aryel A   Briker Anna A   Kaestner Klaus H KH  

Molecular metabolism 20170112 3


<h4>Objective</h4>α-cells are the second most prominent cell type in pancreatic islets and are responsible for producing glucagon to increase plasma glucose levels in times of fasting. α-cell dysfunction and inappropriate glucagon secretion occur in both type 1 and type 2 diabetes. Thus, there is growing interest in studying both normal function and pathophysiology of α-cells. However, tools to target gene ablation or activation specifically of α-cells have been limited, compared to those availa  ...[more]

Similar Datasets

| S-EPMC5021577 | biostudies-literature
| S-EPMC8627868 | biostudies-literature
| S-EPMC5350237 | biostudies-literature
| S-EPMC5986857 | biostudies-literature
| S-EPMC8713987 | biostudies-literature
| S-EPMC10131096 | biostudies-literature
| S-EPMC10018339 | biostudies-literature
| S-EPMC8000071 | biostudies-literature
| S-EPMC10342586 | biostudies-literature
| S-EPMC6703706 | biostudies-literature